Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility

Drugs

Volumn 70, Issue 8, 2010, Pages 949-964

  Dormn, Gyrgy ^a   Cseh, Sndor ^a   Hajd, Istvn ^a,b   Barna, Lszl ^b   Knya, Dnes ^c   Kupai, Krisztina ^d   Kovcs, Lszl ^c   Ferdinandy, Pter ^d,e  

^a TargetEx ^*  (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Infarmatik   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

^e PHARMAHUNGARY GROUP   (Hungary)

Author keywords

Arthritis; Cancer; Chronic heart failure; Chronic obstructive pulmonary disease; Doxycycline; General; Matrix metalloproteinase inhibitors; Research and development; Therapeutic use; Treatment

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ABT 518; AE 941; AG 3433; APRATASTAT; AZD 8955; BATIMASTAT; BB 2827; BB 3364; CGS 27023A; CIPEMASTAT; CPA 926; D 1927; DERMOSTAT; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ILOMASTAT; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; MMI 270; MPC 2130; PCK 3145; PG 116800; PLACEBO; PRINOMASTAT; PS 508; REBIMASTAT; RO 282653; RO 323555; S 3304; SB 3CT; SOLIMASTAT; TANOMASTAT; TIGAPOTIDE; TMI 05; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 784;

ABDOMINAL PAIN; ACNE; ACUTE CORONARY SYNDROME; ADVANCED CANCER; ARTHRALGIA; ARTHRITIS; BLOOD TOXICITY; BRAIN CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PERIODONTITIS; CLINICAL PHARMACOLOGY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DRUG BINDING SITE; DRUG CONFORMATION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; ENTERITIS; EYE DISEASE; EYE INFLAMMATION; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; INFLAMMATORY DISEASE; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OSTEOARTHRITIS; OVARY CANCER; PANCREAS CANCER; PERIODONTAL DISEASE; PHOTOSENSITIVITY; PROSTATE CANCER; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; ROSACEA; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; X RAY CRYSTALLOGRAPHY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEASE INHIBITORS;

ANIMALIA;

EID: 77952647070     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318390-000000000-00000     Document Type: Review

References (82)

1. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48: 1014-1022
2. Li NG, Shi ZH, Tang YP, et al. Selective matrix metalloprotei-nase inhibitors for cancer. Curr Med Chem 2009; 16: 3805-3827
3. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006; 69: 677-687
4. Johnson AR, Pavlovsky AG, Ortwine DF, et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007; 282: 27781-27791
5. Renkiewicz R, Qiu L, Lesch C, et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced muscu-loskeletal side effects in rats. Arthritis Rheum 2003; 48: 1742-1749
6. Dorman G, Kocsis-Szommer K, Spadoni C, et al. MMP inhibitors in cardiac diseases: an update. Recent Pat Car-diovasc Drug Discov 2007; 2: 186-194
7. Chow AK, Cena J, Schulz R. Acute actions and novel tar-gets of matrix metalloproteinases in the heart and vascu-lature. Br J Pharmacol 2007; 152: 189-205
8. Aureli L, Gioia M, Cerbara I, et al. Structural bases for substrate and inhibitor recognition by matrix metallopro-teinases. Curr Med Chem 2008; 15: 2192-2222
9. Yiotakis A, Dive V. Third-generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Høyer-Hansen G, Blasi F, et al., editors. The cancer degradome: proteases and cancer biology. New York: Springer Science + Business Media, 2008: 811-825
10. Netzel-Arnett S, Sang QX, Moore WG, et al. Comparative sequence specificities of human 72-and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry 1993; 32: 6427-6432
11. Lukacova V, Zhang Y, Mackov M, et al. Similarity of binding sites of human matrix metalloproteinases. J Biol Chem 2004; 279 (14): 14194-14200
12. Pirard B. Insight into the structural determinants for selec-tive inhibition of matrix metalloproteinases. Drug Discov Today 2007 Aug; 12 (15-16): 640-646
13. Pirard B, Matter H. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J Med Chem 2006; 49 (1): 51-69
14. Lukacova V, Khandelwal A, Zhang Y, et al. Selectivity and affinity of matrix metalloproteinase inhibitors. In: Naidoo KJ, Brady J, Field MJ, et al., editors. Modelling molecular structure and reactivity in biological systems. London: Royal Society of Chemistry, 2006: 193-205
15. Pochetti G, Montanari R, Gege C, et al. Extra binding re-gion induced by non-zinc chelating inhibitors into the S(1) subsite of matrix metalloproteinase 8 (MMP-8). J Med Chem 2009; 52 (4): 1040-1049
16. Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol 2005 Feb; 12 (2): 181-189
17. Papp A, Szommer T, Barna L, et al. Enhanced hit-to-lead process using bioanalogous lead evolution and chemoge-nomics: application in designing selective matrix metallopro-tease inhibitors. Expert Opin Drug Discov 2007; 2 (5): 1-17
18. Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 2007; 15: 2223-2268
19. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006 Mar; 25 (1): 115-136
20. Jacobsen FE, Lewis JA, Cohen SM. The design of inhibitors for medicinally relevant metalloproteins. Chem Med Chem 2007 Feb; 2 (2): 152-171
21. Hajduk PJ, Sheppard G, Nettesheim D, et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 1997; 119: 5818-5827
22. Nordstrom H, Gossas T, Hamalainen M, et al. Identifica-tion of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem 2008 Jun 26; 51 (12): 3449-3459
23. Takahashi K, Ikura M, Habashita H, et al. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach. Bioorg Med Chem 2005 Jul 15; 13 (14): 4527-4543
24. Puerta DT, Griffin MO, Lewis JA, et al. Heterocyclic zinc-binding groups for use in next-generation matrix metallo-proteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem 2006 Mar; 11 (2): 131-138
25. Jacobsen FE, Lewis JA, Cohen SM. A new role for old li-gands: discerning chelators for zinc metalloproteinases. J Am Chem Soc 2006 Mar 15; 128 (10): 3156-3157
26. Agrawal A, Romero-Perez D, Jacobsen JA, et al. Zinc-binding groups modulate selective inhibition of MMPs. Chem Med Chem 2008 May; 3 (5): 812-820
27. Marimastat: BB 2516, TA 2516. Drugs R D 2003; 4 (3): 198-203
28. Winding B, NicAmhlaoibh R, Misander H, et al. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 2002 Jun; 8: 1932-1939
29. De B, Natchus MG, Cheng M, et al. The next generation of MMP inhibitors: design and synthesis. Ann N Y Acad Sci 1999; 878: 40-60
30. Scatena R. Prinomastat, a hydroxamate-based matrix me-talloproteinase inhibitor: a novel pharmacological approach for tissue remodelling-related diseases. Expert Opin Investig Drugs 2000 Sep; 9 (9): 2159-2165
31. Johnson JL, Fritsche-Danielson R, Behrendt M, et al. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 2006 Aug 1; 71 (3): 586-595
32. Hu Y, Xiang JS, DiGrandi MJ, et al. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg Med Chem 2005; 13: 6629-6644
33. Wada CK. The evolution of the matrix metalloproteinase inhibitor drug discovery program at Abbott laboratories. Curr Top Med Chem 2004; 4: 1255-1267
34. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61: 8480-8485
35. Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999; 5: 3603-3607
36. Lee M, Bernardo MM, Meroueh SO, et al. Synthesis of chiral 2-(4-phenoxy phenylsulfonylmethyl) thiiranes as selective gelatinase inhibitors. Org Lett 2005; 7: 4463-4465
37. Grams F, Brandstetter H, D'Alo S, et al. Pyrimidine-2,4,6-triones: a new effective and selective class of matrix me-talloproteinase inhibitors. Biol Chem 2001; 382: 1277-1285
38. Dive V, Georgiadis D, Matziari M, et al. Phosphinic pep-tides as zinc metalloproteinase inhibitors. Cell Mol Life Sci 2004; 61: 2010-2019
39. Pochetti G, Gavuzzo E, Campestre C, et al. Structural in-sight into the stereoselective inhibition of MMP-8 by en-antiomeric sulfonamide phosphonates. J Med Chem 2006; 49: 923-931
40. Salo T, Soini Y, Oiva J, et al. Chemically modified tetra-cyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition. Int J Cardiol 2006 Aug 28; 111 (3): 358-364
41. Breuer E, Frant J, Reich R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin Ther Patents 2005; 15: 253-269
42. Dublanchet AC, Ducrot P, Andrianjara C, et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Med Chem Lett 2005 Aug 15; 15 (16): 3787-3790
43. Lombard C, Saulnier J, Wallach J. Assays of matrix me-talloproteinases (MMPs) activities: a review. Biochimie 2005; 87: 265-272
44. Cheng XC, Fang H, Xu WF. Advances in assays of matrix metalloproteinases (MMPs) and their inhibitors. J Enzyme Inhib Med Chem 2008; 23 (2): 154-167
45. Lauer-Fields JL, Minond D, Chase PS, et al. High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem 2009; 17: 990-1005
46. Hajduk PJ, Greer J. A decade of fragment-based drug de-sign: strategic advances and lessons learned. Nat Rev Drug Discov 2007; 6: 211-219
47. Saghatelian A, Jessani N, Joseph A, et al. Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci USA 2004; 101: 10000-10005
48. Chan EWS, Chattopadhaya S, Panicker RC, et al. Devel-oping photoactive affinity probes for proteomic profiling: hydroxamate-based probes for metalloproteases. J Am Chem Soc 2004; 126: 14435-14446
49. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13 (3): 333-346
50. Fingleton B. MMPs as therapeutic targets: still a viable op-tion? Semin Cell Dev Biol 2008 Feb; 19 (1): 61-68
51. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006 Sep; 5 (9): 785-799
52. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005; 1: 71-104
53. Fingleton B. MMP inhibitor clinical trials: the past, present, and future. In: Edwards D, Høyer-Hansen G, Blasi F, et al., editors. The cancer degradome: proteases and cancer biology. New York: Springer Science+Business Media, 2008: 759-785
54. Krzeski P, Buckland-Wright C, Balint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007; 9: R109
55. Steward WP, Thomas AL. Marimastat: the clinical devel-opment of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 2000; 9: 2913-2922
56. Pharmaceutical R&D pipeline news. Pharmaprojects, 2009 database. London: Informa UK Ltd, 2009
57. Thabet MM, Huizinga TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006 Nov; 7 (11): 1014-1019
58. Scrip Daily Online 2000 Mar 30; S00659818 [PharmaPro-jects database]
59. Eatock M, Cassidy J, Johnson J, et al. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 2005 Jan; 55 (1): 39-46
60. Saloni S, Chan D. Licensing highlights. IDrugs 2005; 8: 172-7
61. Wielockx B, Libert C, Wilson C. Matrilysin (matrix metallo-proteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev 2004; 15: 111-115
62. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006; 48: 15-20
63. van Beusekom HM, Post MJ, Whelan DM, et al. Metallo-proteinase inhibition by batimastat does not reduce neointi-mal thickening in stented atherosclerotic porcine femoral arteries. Cardiovasc Radiat Med 2003; 4: 186-191
64. Araujo CM, Rando GA, Mauro MF, et al. Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study. Arq Bras Cardiol 2005; 84: 256-260
65. Ferdinandy P. Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 2006; 148: 1-3
66. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and per-oxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138: 532-543
67. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007; 47: 211-242
68. Csonka C, Csont T, Onody A, et al. Preconditioning de-creases ischemia/reperfusion-induced peroxynitrite formation. Biochem Biophys Res Commun 2001; 285: 1217-1219
69. Lalu M, Csonka C, Giricz Z, et al. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Com-mun 2002; 296: 937-941
70. Cheung PY, Sawicki G, Wozniak M, et al. Matrix metallo-proteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833-1839
71. Giricz Z, Lalu MM, Csonka C, et al. Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 2006; 316: 154-161
72. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003; 57: 426-433
73. Sariahmetoglu M, Crawford BD, Leon H, et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phos-phorylation. FASEB J 2007; 21: 2486-2495
74. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardio-vascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-458
75. Kandasamy AD, Schulz R. Glycogen synthase kinase-3b is activated by matrix metalloproteinase-2 mediated proteo-lysis in cardiomyoblasts. Cardiovasc Res 2009 Sep 1; 83 (4): 698-706
76. Bereczki E, Gonda S, Csont T, et al. Overexpression of bi-glycan in the heart of transgenic mice: an antibody micro-array study. J Proteome Res 2007; 6: 854-861
77. Downey JM, Cohen MV. Why do we still not have cardio-protective drugs? Circ J 2009; 73 (7): 1171-1177
78. Overall CM, Kleifeld O. Validating matrix metalloprotei-nases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006; 6: 227-239
79. Coussens LM, Fingleton B, Matrisian LM. Matrix me-talloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-2392
80. Curino AC, Engelholm LH, Yamada SS, et al. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol 2005; 169: 977-985
81. Wagenaar-Miller RA, Engelholm LH, Gavard J, et al. Complementary roles of intracellular and pericellular collagen degradation pathways in vivo. Mol Cell Biol 2007; 27: 6309-6322
82. Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 sig-naling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009; 69: 6223-6231